NCT04223856 2026-05-29EV-302Astellas Pharma IncPhase 3 Active not recruiting886 enrolled 12 charts 1 FDA
NCT02516241 2026-04-20Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial CancerAstraZenecaPhase 3 Active not recruiting1,126 enrolled 52 charts